利福平对健康受试者中卡曲司特甲的药代动力学与安全性的影响:一项随机2×2交叉研究
本随机2×2交叉研究在20名健康日本成人中评估利福平(有机阴离子转运多肽强抑制剂)对卡曲司特甲药代动力学、安全性和耐受性的影响。结果显示,联用利福平后卡曲司特(主要活性代谢物)的Cmax和AUC0-t几何均值比(90%CI)分别为4.78(3.64-6.29)和5.59(4.60-6.79),提示存在药代动力学相互作用;联用利福平时不良事件发生率为25.0%,单用为5.0%。
要点
- 利福平显著增加卡曲司特暴露,Cmax几何均值比4.78,AUC0-t几何均值比5.59。
- 联用利福平后卡曲司特及其代谢物暴露均增加。
- 联用利福平不良事件发生率25.0%,单用5.0%,但药物不良反应未增加。
核心结论
- 卡曲司特甲与利福平联用显著增加卡曲司特暴露,提示存在药代动力学相互作用。
研究设计与样本
- 随机2×2交叉研究,纳入20名健康日本成人,受试者分别接受卡曲司特甲960 mg联用利福平600 mg或单用卡曲司特甲960 mg。
主要发现
- 联用利福平后卡曲司特Cmax几何均值比(90%CI)为4.78(3.64-6.29),AUC0-t几何均值比为5.59(4.60-6.79)。
- 联用利福平增加卡曲司特及其代谢物的暴露。
- 联用利福平不良事件发生率为25.0%(5例),单用为5.0%(1例),但药物不良反应发生率未增加。
关键数值与推荐
- 若Cmax和AUC0-t几何均值比的90%CI落在0.80-1.25范围内,则判定无药物相互作用;本研究结果超出该范围。
临床怎么用
- 临床联用利福平与卡曲司特甲时需警惕卡曲司特暴露显著增加,应关注安全性监测。
局限性
- 本研究为单剂量研究,未评估多次给药或长期联用的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: To evaluate the effect of the combination of carotegrast methyl with rifampicin, a potent inhibitor of organic anion transporter polypeptide, on the pharmacokinetics (PKs), safety and tolerability of carotegrast methyl. METHODS: In this 2 × 2 crossover study in 20 healthy Japanese adults, 10 subjects received carotegrast methyl 960 mg and rifampicin 600 mg on day 1 and received carotegrast methyl 960 mg on day 8. The subjects in the other sequence received the same treatments but in the opposite order. The 90% confidence interval (CI) of the geometric mean ratio of the Cmax and AUC0-t for carotegrast, the main active metabolite of carotegrast methyl, with/without rifampicin was calculated. If the 90% CI fell within the range of 0.80-1.25, this indicated the absence of any drug-drug interaction. Adverse events (AEs) were monitored. RESULTS: The geometric mean ratios (90% CI) of the Cmax and AUC0-t for carotegrast with/without rifampicin were 4.78 (3.64-6.29) and 5.59 (4.60-6.79), respectively, indicating that carotegrast has a PK interaction with rifampicin. The combination with rifampicin increased the exposure of carotegrast and also that of its metabolites. The incidence of any AEs with/without rifampicin was five (25.0%) and one (5.0%), respectively. CONCLUSIONS: Coadministration of carotegrast methyl with rifampicin significantly increased the exposure of carotegrast compared with carotegrast methyl administration alone. In this single dose study, the incidence of AEs of carotegrast methyl with rifampicin increased compared with carotegrast methyl alone, but the incidence of adverse drug reactions did not increase with combination administration.
引用
- Imai H, Oikawa I, Koyama T, et al. Effects of rifampicin on the pharmacokinetics and safety of carotegrast methyl in healthy subjects: A randomized 2 × 2 crossover study. Br J Clin Pharmacol. 2024. PMID: 38408756. doi:10.1111/bcp.16024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。